Leishmaniasis: New insights from an old and neglected disease

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 2, 2012, Pages 109-118

  Antinori, S ^a   Schifanella, L ^a   Corbellino, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIGEN; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; K39 ANTIGEN; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PLACEBO; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

AGGLUTINATION TEST; ANTIMALARIAL DRUG RESISTANCE; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CLIMATE CHANGE; DIARRHEA; DIRECT AGGLUTINATION TEST; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDEMIC DISEASE; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOCOMPROMISED PATIENT; INCIDENCE; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA CHAGASI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA PANAMENSIS; LEISHMANIA TROPICA; LEISHMANIASIS; MALIGNANT NEOPLASTIC DISEASE; MIGRATION; MILITARY DEPLOYMENT; MIXED INFECTION; MUCOSAL LEISHMANIASIS; NEGLECTED DISEASE; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; POST KALA AZAR DERMAL LEISHMANIASIS; PREVALENCE; PRIORITY JOURNAL; RELAPSE; REVIEW; SKIN LEISHMANIASIS; TAXONOMY; UNSPECIFIED SIDE EFFECT; VISCERAL LEISHMANIASIS; VOMITING;

ANIMALS; ANTIPROTOZOAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; NEGLECTED DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84857050658     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1276-0     Document Type: Review

References (90)

1. K Al-Mutawakel C Scutaru A Shami M Sakr DA Groneberg D Quarcoo 2010 Scientometric analysis of the world-wide research efforts concerning Leishmaniasis Parasit Vectors 3 14 20202187 10.1186/1756-3305-3-14
2. DM Pratt JR David 1981 Monoclonal antibodies that distinguish between New World species of Leishmania Nature 291 581 583 6787433 1:STN:280: DyaL3M3itV2mtw%3D%3D 10.1038/291581a0 (Pubitemid 11043680)
3. Lainson R, Shaw JJ (1987) Evolution, classification and geographical distribution. In: Peters W, Killick-Kendrick R (eds) The leishmaniases in biology and medicine. Academic Press, London, pp 1-120
4. JA Rioux G Lanotte E Serres F Pratlong P Bastien J Perieres 1990 Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification Ann Parasitol Hum Comp 65 111 125 2080829 1:STN:280:DyaK3M7otFyjtA%3D%3D
5. AL Bañuls M Hide F Prugnolle 2007 Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans Adv Parasitol 64 1 109 17499100 10.1016/S0065-308X(06) 64001-3 (Pubitemid 46702279)
6. J Lukes IL Mauricio G Schönian JC Dujardin K Soteriadou JP Dedet K Kuhls KW Tintaya M Jirků E Chocholová C Haralambous F Pratlong M Oborník A Horák FJ Ayala MA Miles 2007 Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy Proc Natl Acad Sci USA 104 9375 9380 17517634 1:CAS:528:DC%2BD2sXmtlehurk%3D 10.1073/pnas.0703678104 (Pubitemid 47185787)
7. J Fraga AM Montalvo S De Doncker JC Dujardin G Van der Auwera 2010 Phylogeny of Leishmania species based on the heat-shock protein 70 gene Infect Genet Evol 10 238 245 19913110 1:CAS:528:DC%2BC3cXisFGksrk%3D 10.1016/j.meegid.2009.11.007
8. G Schönian I Mauricio E Cupolillo 2010 Is it time to revise the nomenclature of Leishmania? Trends Parasitol 26 466 469 20609626 10.1016/j.pt.2010.06.013
9. C Bern JH Maguire J Alvar 2008 Complexities of assessing the disease burden attributable to leishmaniasis PLoS Negl Trop Dis 2 e313 18958165 10.1371/journal.pntd.0000313
10. SP Singh DC Reddy M Rai S Sundar 2006 Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India Trop Med Int Health 11 899 905 16772012 1:STN:280:DC%2BD28zlvFeluw%3D%3D 10.1111/j.1365-3156.2006. 01647.x (Pubitemid 43846450)
11. VP Singh A Ranjan RK Topno RB Verma NA Siddique VN Ravidas N Kumar K Pandey P Das 2010 Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India Am J Trop Med Hyg 82 9 11 20064987 10.4269/ajtmh.2010.09-0235
12. P Das S Samuels P Desjeux A Mittal R Topno NA Siddiqui D Sur A Pandey R Sarnoff 2010 Annual incidence of visceral leishmaniasis in an endemic area of Bihar, India Trop Med Int Health 15 Suppl 2 4 11 20487422 10.1111/j.1365-3156. 2010.02517.x
13. JC Dujardin L Campino C Cañavate JP Dedet L Gradoni K Soteriadou A Mazeris Y Ozbel M Boelaert 2008 Spread of vector-borne diseases and neglect of Leishmaniasis, Europe Emerg Infect Dis 14 1013 1018 18598618 10.3201/eid1407.071589 (Pubitemid 351920428)
14. PD Ready 2010 Leishmaniasis emergence in Europe Euro Surveill 15 19505 20403308 1:STN:280:DC%2BC3c3nsVSjtw%3D%3D
15. M Maroli L Rossi R Baldelli G Capelli E Ferroglio C Genchi M Gramiccia M Mortarino M Pietrobelli L Gradoni 2008 The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors Trop Med Int Health 13 256 264 18304273 10.1111/j.1365-3156.2007.01998.x (Pubitemid 351316978)
16. G Morosetti G Bongiorno B Beran A Scalone J Moser M Gramiccia L Gradoni M Maroli 2009 Risk assessment for canine leishmaniasis spreading in the north of Italy Geospat Health 4 115 127 19908194
17. A Biglino C Bolla E Concialdi A Trisciuoglio A Romano E Ferroglio 2010 Asymptomatic Leishmania infantum infection in an area of Northwestern Italy (Piedmont Region) where such infections are traditionally nonendemic J Clin Microbiol 48 131 136 19923480 10.1128/JCM.00416-09
18. TJ Naucke C Schmitt 2004 Is leishmaniasis becoming endemic in Germany? Int J Med Microbiol 293 179 181 15147005 (Pubitemid 38962789)
19. TJ Naucke B Menn D Massberg S Lorentz 2008 Sandflies and leishmaniasis in Germany Parasitol Res 103 Suppl 1 S65 S68 19030887 10.1007/s00436-008-1052-y
20. JAR Postigo 2010 Leishmaniasis in the World Health Organization Eastern Mediterranean Region Int J Antimicrob Agents 36 Suppl 1 S62 S65 10.1016/j.ijantimicag.2010.06.023 20728317 1:CAS:528:DC%2BC3cXhtlSmsb7E 10.1016/j.ijantimicag.2010.06.023
21. IM Mosleh E Geith L Natsheh M Abdul-Dayem N Abotteen 2008 Cutaneous leishmaniasis in the Jordanian side of the Jordan Valley: severe under-reporting and consequences on public health management Trop Med Int Health 13 855 860 18363585 10.1111/j.1365-3156.2008.02063.x (Pubitemid 351678633)
22. GAS Romero M Boelaert 2010 Control of visceral leishmaniasis in Latin America-a systematic review PLoS Negl Trop Dis 4 e584 20098726 10.1371/journal.pntd.0000584
23. J Alvar C Cañavate B Gutiérrez-Solar M Jiménez F Laguna R López-Vélez R Molina J Moreno 1997 Leishmania and human immunodeficiency virus coinfection: the first 10 years Clin Microbiol Rev 10 298 319 9105756 1:STN:280:DyaK2s3lvFKmtA%3D%3D (Pubitemid 27196673)
24. J Kubar P Marty A Lelièvre JF Quaranta P Staccini C Caroli-Bosc Y Le Fichoux 1998 Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts AIDS 12 2147 2153 9833855 1:STN:280:DyaK1M%2FkvFKjsw%3D%3D 10.1097/00002030-199816000-00009 (Pubitemid 28495268)
25. R Paredes J Munoz I Diaz P Domingo M Gurgui B Clotet 2003 Leishmaniasis in HIV infection J Postgrad Med 49 39 49 12865570 1:STN:280: DC%2BD3szjtlejug%3D%3D 10.4103/0022-3859.929 (Pubitemid 36758267)
26. J Alvar P Aparicio A Aseffa M Den Boer C Cañavate JP Dedet L Gradoni R Ter Horst R López-Vélez J Moreno 2008 The relationship between leishmaniasis and AIDS: the second 10 years Clin Microbiol Rev 21 334 359 18400800 1:CAS:528:DC%2BD1cXmtFKlsrk%3D 10.1128/CMR.00061-07 (Pubitemid 351555511)
27. R de la Rosa JA Pineda J Delgado J Macías F Morillas JA Mira A Sánchez-Quijano M Leal E Lissen 2002 Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy J Clin Microbiol 40 762 767 10.1128/JCM.40.3.762-767.2002 (Pubitemid 34208620)
28. R ter Horst SM Collin K Ritmeijer A Bogale RN Davidson 2008 Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome Clin Infect Dis 46 1702 1709 18419422 10.1086/587899 (Pubitemid 351706767)
29. S Gorski SM Collin K Ritmeijer K Keus F Gatluak M Mueller RN Davidson 2010 Visceral leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of risk factors and trends PLoS Negl Trop Dis 4 e705 20544032 10.1371/journal.pntd.0000705
30. R Petrela L Kuneshka E Foto F Zavalani L Gradoni 2010 Pediatric visceral leishmaniasis in Albania: a retrospective analysis of 1,210 consecutive hospitalized patients (1995-2009) PLoS Negl Trop Dis 4 e814 10.1371/journal. pntd.0000814
31. S Antinori A Cascio C Parravicini R Bianchi M Corbellino 2008 Leishmaniasis among organ transplant recipients Lancet Infect Dis 8 191 199 18291340 10.1016/S1473-3099(08)70043-4 (Pubitemid 351249252)
32. M Veroux D Corona G Giuffrida B Cacopardo N Sinagra T Tallarita A Giaquinta D Zerbo PF Veroux 2010 Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical features and therapeutic management Transpl Infect Dis 12 387 391 20534033 1:STN:280:DC%2BC3cbjs1WrtQ%3D%3D 10.1111/j.1399-3062.2010.00520.x
33. M Weisser B Khanlari L Terracciano C Arber A Gratwohl S Bassetti C Hatz M Battegay U Flückiger 2007 Visceral leishmaniasis: a threat to immunocompromised patients in non-endemic areas? Clin Microbiol Infect 13 751 753 17610597 1:STN:280:DC%2BD2szptlSjtQ%3D%3D 10.1111/j.1469-0691.2007.01755.x (Pubitemid 47039906)
34. ID Xynos MG Tektonidou D Pikazis NV Sipsas 2009 Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe Emerg Infect Dis 15 956 959 19523302 10.3201/eid1506.090101
35. A Cascio M Iaria C Iaria 2010 Leishmaniasis and biologic therapies for rheumatologic diseases Semin Arthritis Rheum 40 e3 e5 19782386 10.1016/j.semarthrit.2009.07.001
36. F De Leonardis M Govoni A Lo Monaco F Trotta 2009 Visceral leishmaniasis and anti-TNF-α therapy: case report and review of the literature Clin Exp Rheumatol 27 503 506 19604446
37. MC Mueller E Fleischmann M Grunke S Schewe JR Bogner T Löscher 2009 Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab Am J Trop Med Hyg 81 52 54 19556566
38. P Kopterides EG Mourtzoukou E Skopelitis N Tsavaris ME Falagas 2007 Aspects of the association between leishmaniasis and malignant disorders Trans R Soc Trop Med Hyg 101 1181 1189 17870139 10.1016/j.trstmh.2007.08.003 (Pubitemid 350047384)
39. S Antinori E Gianelli S Calattini E Longhi M Gramiccia M Corbellino 2005 Cutaneous leishmaniasis: an increasing threat for travellers Clin Microbiol Infect 11 343 346 15819858 1:STN:280:DC%2BD2M7oslWhug%3D%3D 10.1111/j.1469-0691. 2004.01046.x (Pubitemid 40575815)
40. A Pavli HC Maltezou 2010 Leishmaniasis, an emerging infection in travellers Int J Infect Dis 14 e1032 e1039 20952234 10.1016/j.ijid.2010.06.019
41. E Schwartz C Hatz J Blum 2006 New world cutaneous leishmaniasis in travellers Lancet Infect Dis 6 342 349 16728320 10.1016/S1473-3099(06)70492-3 (Pubitemid 43737272)
42. PJ Weina RC Neafie G Wortmann M Polhemus NE Aronson 2004 Old world leishmaniasis: an emerging infection among deployed US military and civilian workers Clin Infect Dis 39 1674 1680 15578370 10.1086/425747 (Pubitemid 39578545)
43. PP van Thiel T Leenstra HJ de Vries A van der Sluis T van Gool AC Krull M van Vugt PJ de Vries JE Zeegelaar A Bart WF van der Meide HD Schallig WR Faber PA Kager 2010 Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment Am J Trop Med Hyg 83 1295 1300 21118937 10.4269/ajtmh.2010.10-0143
44. ER Lederman LH Weld IRF Elyazar F von Sonnenburg L Loutan E Schwartz JS Keystone 2008 Dermatologic conditions of the ill returned traveler: an analysis from the GeoSentinel Surveillance Network Int J Infect Dis 12 593 602 18343180 10.1016/j.ijid.2007.12.008
45. V Pintado P Martín-Rabadán ML Rivera S Moreno E Bouza 2001 Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study Medicine (Baltimore) 80 54 73 1:STN:280:DC%2BD3M7hvFGgtA%3D%3D 10.1097/00005792-200101000-00006 (Pubitemid 32066379)
46. R López-Vélez 2003 The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV Ann Trop Med Parasitol 97 Suppl 1 143 147 14678641 10.1179/000349803225002615
47. C Mary F Faraut L Lascombe H Dumon 2004 Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity J Clin Microbiol 42 5249 5255 15528722 1:CAS:528:DC%2BD2cXhtFahtL%2FI 10.1128/JCM.42.11.5249-5255. 2004 (Pubitemid 39506237)
48. S Antinori S Calattini R Piolini E Longhi G Bestetti A Cascio C Parravicini M Corbellino 2009 Is real-time polymerase chain reaction (PCR) more useful than a conventional PCR for the clinical management of leishmaniasis? Am J Trop Med Hyg 81 46 51 19556565 1:CAS:528:DC%2BD1MXovFOqsLo%3D
49. N Bourgeois P Bastien J Reynes A Makinson I Rouanet L Lachaud 2010 'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients HIV Med 11 670 673 20500233 1:STN:280:DC%2BC3cbit12jsg%3D%3D 10.1111/j.1468-1293.2010.00846.x
50. S Antinori E Longhi G Bestetti R Piolini V Acquaviva A Foschi S Trovati C Parravicini M Corbellino L Meroni 2007 Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome Br J Dermatol 157 1032 1036 17854365 1:CAS:528: DC%2BD2sXhtlyrsb7L 10.1111/j.1365-2133.2007.08157.x (Pubitemid 47583507)
51. S Sinha G Fernández R Kapila WC Lambert RA Schwartz 2008 Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome Int J Dermatol 47 1263 1270 19126013 10.1111/j.1365-4632.2008.03804.x
52. S Dettwiler T McKee K Hadaya F Chappuis C van Delden S Moll 2010 Visceral leishmaniasis in a kidney transplant recipient: parasitic interstitial nephritis, a cause of renal dysfunction Am J Transpl 10 1486 1489 1:STN:280:DC%2BC3crgvFamtA%3D%3D 10.1111/j.1600-6143.2010.03125.x
53. I Simon KM Wissing V Del Marmol S Antinori M Remmelink E Nilufer Broeders JL Nortier M Corbellino D Abramowicz A Cascio 2011 Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature Transpl Infect Dis 10.1111/j.1399-3062.2011.00598.x
54. R Reithinger JC Dujardin H Louzir C Pirmez B Alexander S Brooker 2007 Cutaneous leishmaniasis Lancet Infect Dis 7 581 596 17714672 10.1016/S1473-3099(07)70209-8 (Pubitemid 47277438)
55. OE Akilov A Khachemoune T Hasan 2007 Clinical manifestations and classification of Old World cutaneous leishmaniasis Int J Dermatol 46 132 142 17269962 10.1111/j.1365-4632.2007.03154.x (Pubitemid 46671686)
56. M Maniscalco G Noto L Zichichi S Veraldi 2007 Multifocal cutaneous leishmaniasis: a new clinical presentation of the disease Acta Derm Venereol 87 275 276 17533501 (Pubitemid 47226903)
57. JAL Lindoso RN Barbosa MP Posada-vergara MIS Duarte LK Oyafuso VS Amato H Goto 2009 Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World Br J Dermatol 160 311 318 19187345 1:STN:280: DC%2BD1M7hsVKmtQ%3D%3D 10.1111/j.1365-2133.2008.08908.x
58. S Antinori S Calattini E Longhi G Bestetti R Piolini C Magni G Orlando M Gramiccia V Acquaviva A Foschi S Corvasce C Colomba L Titone C Parravicini A Cascio M Corbellino 2007 Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature Clin Infect Dis 44 1602 1610 17516404 1:CAS:528:DC%2BD2sXntlWlurk%3D 10.1086/518167 (Pubitemid 46871507)
59. E Bensoussan A Nasereddin F Jonas LF Schnur CL Jaffe 2006 Comparison of PCR assays for diagnosis of cutaneous leishmaniasis J Clin Microbiol 44 1435 1439 16597873 1:CAS:528:DC%2BD28XkvVamtrw%3D 10.1128/JCM.44.4.1435-1439.2006
60. S Verma R Kumar GK Katara LC Singh NS Negi V Ramesh P Salotra 2010 Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis PLoS One 5 e10107 20404924 10.1371/journal.pone.0010107
61. I Romero J Téllez Y Suárez M Cardona R Figueroa A Zelazny N Gore Saravia 2010 Viability and burden of Leishmania in extralesional sites during human dermal leishmaniasis PLoS Negl Trop Dis 4 e819 10.1371/journal. pntd.0000819
62. P Srivastava A Dayama S Mehrotra S Sundar 2011 Diagnosis of visceral leishmaniasis Trans R Soc Trop Med Hyg 105 1 6 21074233 10.1016/j.trstmh.2010. 09.006
63. M Boelaert S El-Safi A Hailu M Mukhtar S Rijal S Sundar M Wasunna A Aseffa J Mbui J Menten P Desjeux RW Peeling 2008 Diagnostic tests for Kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent Trans R Soc Trop Med Hyg 102 32 40 17942129 1:STN:280:DC%2BD2sjhvVCmsg%3D%3D 10.1016/j.trstmh.2007.09.003 (Pubitemid 350185837)
64. S Pattabhi J Whittle R Mohamath S El-Safi GG Moulton JA Guderian D Colombara AO Abdoon MM Mukhtar D Mondal J Esfandiari S Kumar P Chun SG Reed A Bhatia 2010 Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis PLoS Negl Trop Dis 4 e822 10.1371/journal.pntd.0000822
65. S Sundar J Chakravarty D Agarwal M Rai HW Murray 2010 Single-dose liposomal amphotericin B for visceral leishmaniasis in India N Engl J Med 362 504 512 20147716 1:CAS:528:DC%2BC3cXitlagsrg%3D 10.1056/NEJMoa0903627
66. S Sundar G Agrawal M Rai MK Makharia HW Murray 2001 Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial BMJ 323 419 422 11520836 1:CAS:528: DC%2BD3MXntVKnsr4%3D 10.1136/bmj.323.7310.419 (Pubitemid 32801392)
67. S Sundar TK Jha CP Thakur M Mishra VP Singh R Buffels 2003 Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study Clin Infect Dis 37 800 804 12955641 1:CAS:528: DC%2BD3sXot1Wit7k%3D 10.1086/377542 (Pubitemid 37153659)
68. V Syriopoulou GL Daikos M Theodoridou I Pavlopoulou AG Manolaki E Sereti A Karamboula D Papathanasiou X Krikos G Saroglou 2003 Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis Clin Infect Dis 36 560 566 12594635 1:CAS:528:DC%2BD3sXisFals70%3D 10.1086/367843 (Pubitemid 36259559)
69. SK Bhattacharya PK Sinha S Sundar CP Thakur TK Jha K Pandey VR Das N Kumar C Lal N Verma VP Singh A Ranjan RB Verma G Anders H Sindermann NK Ganguly 2007 Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis J Infect Dis 196 591 598 17624846 1:CAS:528:DC%2BD2sXps1Shu74%3D 10.1086/519690 (Pubitemid 47206107)
70. K Ritmeijer A Dejenie Y Assefa TB Hundie J Mesure G Boots M den Boer RN Davidson 2006 A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection Clin Infect Dis 43 357 364 16804852 1:CAS:528:DC%2BD28XnvVOit7o%3D 10.1086/505217 (Pubitemid 44078909)
71. H Sindermann KR Engel C Fischer W Bommer 2004 Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection Clin Infect Dis 39 1520 1523 15546090 1:CAS:528: DC%2BD2cXhtFCrurfO 10.1086/425359 (Pubitemid 39518218)
72. J Soto BA Arana J Toledo N Rizzo JC Vega A Diaz M Luz P Gutierrez M Arboleda JD Berman K Junge J Engel H Sindermann 2004 Miltefosine for New World cutaneous leishmaniasis Clin Infect Dis 38 1266 1272 15127339 1:CAS:528:DC%2BD2cXksFers7Y%3D 10.1086/383321 (Pubitemid 38608569)
73. M Mohebali A Fotouhi B Hooshmand Z Zarei B Akhoundi A Rahnema AR Razaghian MJ Kabir A Nadim 2007 Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran Acta Trop 103 33 40 17586452 1:CAS:528:DC%2BD2sXotVWrtbg%3D 10.1016/j.actatropica.2007.05.005 (Pubitemid 47078934)
74. J Soto J Rea M Balderrama J Toledo P Soto L Valda JD Berman 2008 Efficacy of miltefosine for Bolivian cutaneous leishmaniasis Am J Trop Med Hyg 78 210 211 18256415 (Pubitemid 351844550)
75. I Vélez L López X Sánchez L Mestra C Rojas E Rodríguez 2010 Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis Am J Trop Med Hyg 83 351 356 20682881 10.4269/ajtmh.2010.10-0060
76. PPAM van Thiel T Leenstra PA Kager HJ de Vries M van Vugt WF van der Meide A Bart JE Zeegelaar A van der Sluis HDFH Schallig T van Gool WR Faber PJ de Vries 2010 Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan Clin Infect Dis 50 80 83 19951107 10.1086/648726
77. PR Machado J Ampuero LH Guimarães L Villasboas AT Rocha A Schriefer RS Sousa A Talhari G Penna EM Carvalho 2010 Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial PLoS Negl Trop Dis 4 e912 21200420 10.1371/journal.pntd.0000912
78. A Chrusciak-Talhari R Dietze C Chrusciak Talhari RM da Silva EP Gadelha Yamashita G de Oliveira Penna PR Lima Machado S Talhari 2011 Randomized controlled clinical trial to assess efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil Am J Trop Med Hyg 84 255 260 21292895 1:CAS:528: DC%2BC3MXisF2nsbg%3D 10.4269/ajtmh.2011.10-0155
79. Y Keynan OE Larios MC Wiseman M Plourde M Ouellette E Rubinstein 2008 Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan Can J Infect Dis Med Microbiol 19 394 396 19436567
80. U González M Pinart L Reveiz M Rengifo-Pardo J Tweed A Macaya J Alvar 2010 Designing and reporting clinical trials on treatments for cutaneous leishmaniasis Clin Infect Dis 51 409 419 20624067 10.1086/655134
81. VS Amato FF Tuon AM Siqueira AC Nicodemo VA Neto 2007 Treatment of mucosal leishmaniasis in Latin America: systematic review Am J Trop Med Hyg 77 266 274 17690398 1:CAS:528:DC%2BD2sXhtVWqtb%2FP (Pubitemid 351859275)
82. S Sundar TK Jha CP Thakur PK Sinha SK Bhattacharya 2007 Injectable paromomycin for visceral leishmaniasis in India N Engl J Med 356 2571 2581 17582067 1:CAS:528:DC%2BD2sXmslKjsr4%3D 10.1056/NEJMoa066536 (Pubitemid 46961002)
83. A Hailu A Musa M Wasunna M Balasegaram S Yifru G Mengistu Z Hurissa W Hailu T Weldegebreal S Tesfaye E Makonnen E Khalil O Ahmed A Fadlalla A El-Hassan M Raheem M Mueller Y Koummuki J Rashid J Mbui G Mucee S Njoroge V Manduku A Musibi G Mutuma F Kirui H Lodenyo D Mutea G Kirigi T Edwards P Smith L Muthami C Royce S Ellis M Alobo R Omollo J Kesusu R Owiti J Kinuthia Leishmaniasis East Africa Platform (LEAP) group 2010 Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial PLoS Negl Trop Dis 4 e709 21049059 10.1371/journal.pntd.0000709
84. F Chappuis E Alirol DT Worku Y Mueller K Ritmeijer 2011 High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B Antimicrob Agents Chemother 55 455 456 21078947 1:CAS:528:DC%2BC3MXisVegtr4%3D 10.1128/AAC.01298-10
85. AM Musa B Younis A Fadlalla C Royce M Balasegaram M Wasunna A Hailu T Edwards R Omollo M Mudawi G Kokwaro A El-Hassan E Khalil 2010 Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study PLoS Negl Trop Dis 4 e855 21049063 10.1371/journal.pntd. 0000855
86. DH Kim HJ Chung J Bleys RF Ghohestani 2009 Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials PLoS Negl Trop Dis 3 e381 19221595 10.1371/journal.pntd.0000381
87. PL Olliaro 2010 Drug combinations for visceral leishmaniasis Curr Opin Infect Dis 29 595 602 10.1097/QCO.0b013e32833fca9d
88. J van Griensven M Balasegaram F Meheus J Alvar L Lynen M Boelaert 2010 Combination therapy for visceral leishmaniasis Lancet Infect Dis 10 184 194 20185097 10.1016/S1473-3099(10)70011-6
89. F Meheus M Balasegaram P Olliaro S Sundar S Rijal MA Faiz M Boelaert 2010 Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent PLoS Negl Trop Dis 4 e818 10.1371/journal.pntd. 0000818
90. S Sundar PK Sinha M Rai DK Verma K Nawin S Alam J Chakravarty M Vaillant N Verma K Pandey P Kumari CS Lal R Arora B Sharma S Ellis N Strub-Wourgaft M Balasegaram P Olliaro P Das F Modabber 2011 Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial Lancet 377 477 486 10.1016/S0140-6736(10)62050-8 21255828 1:CAS:528:DC%2BC3MXhsFOqtLk%3D 10.1016/S0140-6736(10)62050-8